CADRENAL THERAPEUTICS INC

Cadrenal insider sale: CEO Pham Quang X sells 9,167 shares amid a steep decline, revealing liquidity needs yet long‑term conviction. Investors weigh short‑term risk vs future pipeline gains.

Cadrenal Therapeutics insider selling trend: CEO Pham Quang X sells shares via Rule 10b‑5‑1 at low prices, sparking investor concern amid a 71.66 % YTD decline.

Cadrenal Therapeutics CEO sells 1,165 shares at $5.69, sparking a brief 7.7% rally driven by social‑media buzz—insider moves, funding challenges, and tecarfarin’s future weigh in.